The catalytic domain of free or ligand bound histone deacetylase 4 occurs in solution predominantly in closed conformation
AbstractHuman histone deacetylase 4 (HDAC4) is a key epigenetic regulator involved in a number of important cellular processes. This makes HDAC4 a promising target for the treatment of several cancers and neurodegenerative diseases, in particular Huntington's disease. HDAC4 is highly regulated by phosphorylation and oxidation, which determine its nuclear or cytosolic localization, and exerts its function through multiple interactions with other proteins, forming multiprotein complexes of varying composition. The catalytic domain of HDAC4 is known to interact with the SMRT/NCOR corepressor complex when the structural zinc-b...
Source: Protein Science - February 15, 2024 Category: Biochemistry Authors: Markus Schweipert,
Thomas Nehls,
Anton Fr ühauf,
Cecilé Debarnot,
Adarsh Kumar,
Stefan Knapp,
Frederik Lermyte,
Franz‐Josef Meyer‐Almes Tags: RESEARCH ARTICLE Source Type: research
Pooling of primary care electronic health record (EHR) data on Huntingtons disease (HD) and cancer: establishing comparability of two large UK databases
Conclusions
Differences in cancer incidence trends between 1990 and 2000 may relate to use of a practice-level data quality filter (the ‘up-to-standard’ date) in CPRD GOLD only. As well as the impact of data curation methods, differences in underlying data models can make it more challenging to define exactly equivalent clinical concepts in each database. Researchers should be aware of these potential sources of variability when planning combined database studies and interpreting results. (Source: BMJ Open)
Source: BMJ Open - February 14, 2024 Category: General Medicine Authors: Dedman, D., Williams, R., Bhaskaran, K., Douglas, I. J. Tags: Open access, Epidemiology Source Type: research
Huntington disease – Update on ongoing therapeutic developments and a look toward the future
Huntington's disease (HD) is a genetic condition inherited in an autosomal dominant pattern characterized by neurodegeneration. The root cause of HD is a CAG tract expansion occurring in exon 1 of the huntingtin (HTT) gene. This mutation sets in motion a series of detrimental events that progressively lead to neuronal death and structural changes, mainly within the central nervous system but also affecting other organs [1]. Currently, no disease-modifying treatments for HD exist, but an active research effort focuses on potential therapies, with programs in various stages of development. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - February 13, 2024 Category: Neurology Authors: Cristina Sampaio Tags: Review article Source Type: research
Recent advances in Non-Huntington's disease choreas
Chorea is primarily due to an imbalance of basal ganglia output pathways, often due to dysfunction or degeneration of the caudate nucleus and putamen, and can be due to many causes. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - February 12, 2024 Category: Neurology Authors: Molly C. Cincotta, Ruth H. Walker Tags: Review article Source Type: research
CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress
Cell Death & Disease, Published online: 10 February 2024; doi:10.1038/s41419-024-06523-xCHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress (Source: Cell death and disease)
Source: Cell death and disease - February 10, 2024 Category: Internal Medicine Authors: Xuanzhuo Liu Fang Wang Xinman Fan Mingyi Chen Xiaoxin Xu Qiuhong Xu Huili Zhu Anding Xu Mahmoud A. Pouladi Xiaohong Xu Source Type: research
Real-world Survival, Healthcare Resource Utilization, and Costs among U.S. Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-GemOx in the Relapsed/Refractory Setting
Little recent real-world evidence exists on overall survival, healthcare resource utilization (HCRU), and costs among R/R DLBCL patients treated with the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx), a widely-used regimen for patients ineligible for stem cell transplant due to age or comorbidities. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 8, 2024 Category: Hematology Authors: Mahek Garg, Justin Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa A. Doshi, Scott F. Huntington Source Type: research
Emerging antibody-based therapies for Huntington's disease: current status and perspectives for future development
Expert Rev Neurother. 2024 Feb 7:1-14. doi: 10.1080/14737175.2024.2314183. Online ahead of print.ABSTRACTINTRODUCTION: Being an inherited neurodegenerative disease with an identifiable genetic defect, Huntington's disease (HD) is a suitable candidate for early intervention, possibly even in the pre-symptomatic stage. Our recent advances in elucidating the pathogenesis of HD have revealed a series of novel potential therapeutic targets, among which immunotherapies are actively pursued in preclinical experiments.AREAS COVERED: This review focuses on the potential of antibody-based treatments targeting various epitopes (of mu...
Source: Expert Review of Neurotherapeutics - February 7, 2024 Category: Neurology Authors: Anamaria Jurcau Aurel Simion Maria Carolina Jurcau Source Type: research
